Stem Cell Clinic

UAE’s first bone marrow transplant patient tells of life-saving treatment – The National

By Stem Cell Doctors

The first patient in the UAE to undergo a bone-marrow transplant using stem cell technology has told of how the treatment saved his life.

Abdullah Nazir Ahmad Muhammad, an electrician from Pakistan, faced terminal decline when doctors put him forward for the ground breaking treatment.

After he began to vomit blood, the 49-year-old had blood cancer diagnosed in 2018. Doctors said his health had begun to rapidly deteriorate and his only option was to undergo an expensive bone marrow transplant.

"I didnt have money to get a transplant and the UAE sponsored my treatment. I am happy to be first one to undergo this transplant in the UAE. It wouldnt have been able to afford it in Pakistan, said the father-of-four, whose family live in the Khanewal district.

I didnt have money to get a transplant and the UAE sponsored my treatment. I am happy to be first one to undergo this transplant in the UAE

Abdullah Nazir Ahmad Muhammad

Mr Muhammad received his transplant on July 18 at Sheikh Khalifa Medical City with involvement of Abu Dhabi Stem Cells Centre the facility developing a stem cell treatment for Covid-19 patients.

The transplant procedure will bring hope to cancer patients in the UAE, who can now seek treatment closer to home to remain with family.

Known as regenerative medicine, stem cell therapy promotes the repair of abnormal or injured tissue using stem cells. Doctors can manipulate the cells into the type the patient needs and inject them where repair is necessary. The cells can be taken from a matching donor or harvested from the patient, treated, then reintroduced to the body.

The UAE has began to harness stem cell therapy in recent months to fight the coronavirus but this was the first time it was used in a transplant in the Emirates.

In Mr Muhammeds case, stem calls were harvested from his own blood and were reinjected into him after he underwent a short course of chemotherapy. This is called an autologous bone marrow transplant.

Dr Fatima Al Kaabi, executive director of the Abu Dhabi Bone Marrow Transplant Programme, described the treatment as a milestone for the UAE.

"Most of these cases travel abroad so, in the near future, we will be self sufficient and efficient to take care of our own with the highest calibre of medical care and international standards."

Dr Al Kaabi said that, to harvest the cells, Mr Muhammed was injected with a stimulant that prompted the stem cells to leave his bone marrow and enter his blood stream. His blood was drawn using a machine similar to one used in kidney dialysis to separate the plasma containing the stem cells from the blood.

The plasma was safely stored while Mr Muhammed underwent chemotherapy to wipe out the bone marrow and give way to the new cells, she said.

Mr Muhammed was kept in a sterile area for 10 to 15 days to prevent him from catching infections until the stem cells were returned to his body. The reintroduction of cells to his body took about 20 minutes.

Following the successful autologous bone marrow transplant, Abu Dhabi Stem Cells Centre aims to begin carrying out transplants from related donors.

For now only we are doing autologous transplants, where the patient and donor are the same person, but in the near future we will not only do related transplantation but more complicated ones where donors are not related to the patient, said Dr Yendry Ventura, general manager of the stem cell centre and director of Abu Dhabi Bone Marrow Transplant Programme.

Sheikh Khalifa Medical City and the Department of Health Abu Dhabi are working on a stem cell donor registry.

The next transplant is scheduled in a few weeks time with the centre aiming to perform 10 transplants before the related transplant programme and, eventually, a transplant programme for children.

We want to provide the people of UAE a programme that is not only comparable with any other programmes in the rest of the world but also offers customised and personalised treatment," Dr Ventura said.

Mr Muhammed, who has been in hospital since July 8, will be released in a few days and plans to return to Pakistan in October to see his family.

Updated: July 28, 2020 09:05 PM

See original here:
UAE's first bone marrow transplant patient tells of life-saving treatment - The National

From cancer through Covid, how one mother retained hope – Buffalo News

By Stem Cell Doctors

Even in March, when she learned she had Covid-19, she thought she would soon go home.

On the day of her release from Roswell, Melissa Fuller is greeted by her son Jacob.

Normally, said Dr. Philip McCarthy, director of Roswells transplant and cellular therapy program, shed have cleared the virus in two to three weeks, but because her immune system wasn't strong enough, it took what seemed like forever.

She was at the cancer center from late winter into summer. The staff, intensely aware of that journey, speaks of Melissa with affection and a touch of awe. In 2016, she was working in payroll at the Madison-Oneida BOCES when she went to the doctor for shoulder pain she thought was triggered by a torn rotator cuff.

The ache was radiating from a tumor. McCarthy said she had an especially aggressive form of multiple myeloma, acancer of the bone. Melissa would eventually go through a stem cell transplant at the SUNY Upstate University Medical Center in Syracuse that she hoped would roll back the disease.

The transplant didnt work. Her doctor at Upstate, an oncologist who became a friend, told her quietly that she was running out of options. She suggested Melissa look to Roswell and its CAR T-cell therapy, leading her to McCarthy, who moved quickly based on the dire nature of the risk.

His team injected Melissa with her own healthy T-cells to recognize and kill her cancer, treatments that continued throughout her stay in February. The process was a success, McCarthy said. Most of her cancer disappeared, offering the greatest hope her family had felt for years.

Continued here:
From cancer through Covid, how one mother retained hope - Buffalo News

Orthopedic Regenerative Medicine Market Research Report 2020 Overall Analysis and Forecast up to the Year 2027 – Sanford Philosopher

By Adult Stem Cells

Orthopedic Regenerative Medicine Market Report is an objective and comprehensive study of the current state expected at the major drivers, market strategies, and key vendors growth. The study also includes the important achievements of the market, Research & development and regional growth of the leading competitors operating in the market.

This report also explain the numerous factors that form a significant element of the market. It includes the definition and the scope of the market with a detailed explanation of the market drivers, opportunities, restraints, and threats.

Get Sample Report (including full TOC, Tables and Figures): https://www.coherentmarketinsights.com/insight/request-sample/3566

Leading players of Orthopedic Regenerative Medicine Market:

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Orthopedic Regenerative Medicine Geographical Segmentation Includes:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of L.A.)

Middle East and Africa (Turkey, GCC)

The research report includes an exploration of the competitive landscape present in the Orthopedic Regenerative Medicine Market. It includes an import of the current and future trends that players can invest in. Likewise, it also includes an estimation of the business outlooks of the players and explains the nature of the competition.

Orthopedic Regenerative Medicine Market Segmentation

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

The plus point of this research study is that it includes the impact of COVID-19 to the Orthopedic Regenerative Medicine market. The data summarized within this research study includes forecast from 2020 to 2027. COVID-19 has significantly impacted each and every market on the global platform. If you have any specific requirement then Please get in touch with us. Our Expert team will provide as per report customized to your requirement.

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase GlobalOrthopedic Regenerative Medicine Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/3566

Important Features of the report:

Reasons for buying this report:

It offers the regional analysis of the Orthopedic Regenerative Medicine Market along with the business profiles of several stakeholders.

Some Major TOC Points:

Chapter 1. Orthopedic Regenerative Medicine Market Report Overview

Chapter 2. Orthopedic Regenerative Medicine industry Growing Trends

Chapter 3. Market Share by Key vendors

Chapter 4. Orthopedic Regenerative Medicine Market Breakdown Data by Type and Application

Chapter 5. Orthopedic Regenerative Medicine Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Orthopedic Regenerative Medicine Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Factors

And Many More

Buy this Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

Contacts US

Mr. Shah Email:[emailprotected] Phone: US +1-206-701-6702/UK +44-020 8133 4027

See original here:
Orthopedic Regenerative Medicine Market Research Report 2020 Overall Analysis and Forecast up to the Year 2027 - Sanford Philosopher

The Global CO2 Incubator Market is expected to grow by $ 100.29 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period -…

By Stell Cell Research

NEW YORK, July 28, 2020 /PRNewswire/ -- The analyst has been monitoring the CO2 incubator market and it is poised to grow by $ 100.29 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period. Our reports on CO2 incubator market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Read the full report: https://www.reportlinker.com/p03334934/?utm_source=PRN

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the growth of the global life science market and investments in the global laboratory instrumentation market. The CO2 incubator market analysis includes end-user segment and geographic landscape.

The CO2 incubator market is segmented as below: By End-user Biotechnology and pharmaceutical companies Research and clinical laboratories Others

By Geographic Landscapes APAC North America Europe MEA South America

This study identifies the increase in stem cell research as one of the prime reasons driving the CO2 incubator market growth during the next few years. The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our CO2 incubator market covers the following areas: CO2 incubator market sizing CO2 incubator market forecast CO2 incubator market industry analysis

Read the full report: https://www.reportlinker.com/p03334934/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

See the original post:
The Global CO2 Incubator Market is expected to grow by $ 100.29 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period -...

Stem Cell Banking Expected to Witness a Fast-paced Growth Over the Forecast Period 2018 2026 – Owned

By Stell Cell Research

With reliable and impactful research methodologies, PMR provides critical information pertaining to the growth of the global Stem Cell Banking market. Our team of analysts monitor the ongoing developments within the Stem Cell Banking space and provide an unbiased assessment of the global Stem Cell Banking market. The data included in the report are procured from reliable and trustworthy primary and secondary sources.

According to the findings of the report, the value of the global Stem Cell Banking market in 2018 was ~US$ XX (Mn/Bn) and expected to attain a value of ~US$ XX (Mn/Bn) by the end of 2029. In addition, the report reveals that the global Stem Cell Banking market is likely to grow at a CAGR of XX% during the forecast period (2019-2029).

Request Sample Report @ https://www.persistencemarketresearch.co/samples/22819

Some of the leading companies profiled in the market study include:

The Stem Cell Banking market report provides an extensive analysis of the different product types including:

The presented market study includes a brief introduction of the Stem Cell Banking market to enhance the reading experience of our users. Further, a thorough quantitative and qualitative analysis of each of these segments is provided in the report along with graphs, tables, and figures to support the data.

key players of the global stem cell banking market are NeoStem, Esperite, Smart Cells International, StemCyte, ViaCord, Capricor, CordCare, Cryo Stemcell, Cellartis and Aldagen. The key players from the North America and Europe are contributing major share to the global stem cells banking market.

Overall, the global stem cell banking market has expected to register the significant growth over the forecast period.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/22819

Key information drawn from the Stem Cell Banking market study

The market report aims to address the following queries:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/22819

View post:
Stem Cell Banking Expected to Witness a Fast-paced Growth Over the Forecast Period 2018 2026 - Owned

Stem Cell & Regenerative Medicine Specialist – Greenville …

By Stem Cell Medicine

What is regenerative medicine?

Regenerative medicine consists of cutting-edge therapies that concentrate on healing substances found in the human body. Research suggests that regenerative medicine may help your body repair damaged tissues. The two main types of regenerative medicine are PRP serums and MSC therapies.

Your blood is filled with tiny plate-shaped cell fragments called platelets. Platelets are the type of cell your body uses to coagulate your blood to stop a wound from bleeding and to help rebuild tissue as you heal. Platelets are among the solids that make up your blood.

The liquid part of your blood is called plasma. When your licensed medical expert makes a PRP serum, they start by taking a small donation of blood from your arm. They spin that in a sterile centrifuge to separate the platelets from the plasma.

Your medical expert mixes all of the healing platelets into a much smaller amount of your plasma. You then have a concentration of healing platelets thats about 5-10 times stronger than your blood.

At the Carolinas Center for Advanced Management of Pain, MSC therapy is created with donated, pre-approved, and pre-screened stem cells derived from the umbilical cords of healthy, full-term, live births. Umbilical cords are rich in mesenchymal stem cells but are usually discarded.

MSCs are blank slate cells that have the ability to transform themselves into other cells. When injected into an area of injury, MSCs have the potential to become tendon cells, bone cells, or skin cells, among others.

If youre getting PRP, your licensed medical practitioner first uses a syringe to withdraw blood and create the serum. The entire process takes about 15 minutes.

When your PRP or MSC serum is ready, your expert injects it directly into your area of pain or damage. The healing platelets or MSCs are thought to accelerate your own bodys healing process, helping it to rebuild tissues with new proteins and cells. Research has shown that as your body heals the underlying injury, your pain may be reduced, too.

To find out if regenerative medicine is the right therapy for you, contact the Carolinas Center for Advanced Management of Pain office nearest you. Phone the friendly staff or use the convenient online scheduler.

See the rest here:
Stem Cell & Regenerative Medicine Specialist - Greenville ...

Advances in Treating Non-Small Cell Lung Cancer – GlobeNewswire

By Stem Cell Treatment

July 28, 2020 17:09 ET | Source: Family Features

photo-release

Photo courtesy of Getty Images

MISSION, Kan., July 28, 2020 (GLOBE NEWSWIRE) -- (Family Features) Despite progress in treating lung cancer, it is the leading cause of cancer deaths and impacts communities across the United States. The most common form of lung cancer is non-small cell lung cancer (NSCLC). NSCLC is a complex disease that can be challenging to treat, which may feel overwhelming and unsettling for people facing the disease.

Advanced lung cancer is devastating, so the fact that additional treatment options are now available that have the potential to extend the lives of patients gives us hope, said Bonnie J. Addario, lung cancer survivor and co-founder and chair, GO2 Foundation. Its exciting that this is a combination of immunotherapies, which brings a whole new approach for patients and physicians to consider when discussing treatment options.

A Chemo-Free Treatment Option A first-of-its-kind, chemotherapy-free treatment option was recently approved by the U.S. Food and Drug Administration as a first treatment for certain adults with advanced NSCLC, or NSCLC that has spread to other parts of the body. This treatment is a prescription medicine that is a combination of two immunotherapies, Opdivo (nivolumab) and Yervoy (ipilimumab), and it can be used for adults newly diagnosed with advanced NSCLC that tests positive for PD-L1 but do not have an abnormal EGFR or ALK gene.

Opdivo can cause problems that can sometimes become serious or life threatening and can lead to death. Serious side effects may include lung problems (pneumonitis); intestinal problems (colitis) that can lead to tears or holes in your intestine; liver problems (hepatitis); hormone gland problems (especially the thyroid, pituitary, adrenal glands, and pancreas); kidney problems, including nephritis and kidney failure; skin problems; inflammation of the brain (encephalitis); problems in other organs; severe infusion reactions; and complications of stem-cell transplant that uses donor stem cells (allogeneic). Additional serious side effects of Yervoy alone include: nerve problems that can lead to paralysis; eye problems; and complications of stem-cell transplant that uses donor stem cells (allogeneic). Please see Important Facts about side effects for Opdivo and Yervoy below.

The Chance for a Longer Life In a study of 793 previously untreated patients whose tumors tested positive for PD-L1, 396 were given the immunotherapy combination of Opdivo + Yervoy and 397 were given platinum-based chemotherapy. Treatment with the immunotherapy combination reduced the risk of death by 21%, with half of patients treated with the immunotherapy combination still alive at 17.1 months and half of patients treated with platinum-based chemotherapy still alive at 14.9 months. This analysis was conducted at a minimum follow-up of 29.3 months.

In additional analyses, 63% of patients treated withthe immunotherapy combinationand 56% treated with platinum-based chemotherapy were alive at one year, and 40% and 33% at two years, respectively.At three years, 33% of patients treated withthe immunotherapy combination and 22% of those treated with platinum-based chemotherapy were still alive. The analysis at these time points was not designed to show a difference between Opdivo + Yervoy and platinum-based chemotherapy.

The most common side effects of OPDIVO, when used in combination with YERVOY, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection; headache; low thyroid hormone levels (hypothyroidism); decreased weight; and dizziness. The most common side effects of YERVOY include: feeling tired; diarrhea; nausea; itching; rash; vomiting; headache; weight loss; fever; decreased appetite; and difficulty falling or staying asleep. Please see Important Facts about side effects for Opdivo and Yervoy below.

As an oncologist who treats patients facing this particularly challenging disease, the fact that Opdivo plus Yervoy has shown overall survival at three years is important, said Hossein Borghaei, D.O., chief of thoracic medical oncology division at Fox Chase Cancer Center and an investigator in the clinical study.

Being diagnosed with lung cancer can be challenging and life-changing. Advancements in NSCLC bring additional treatment options that may enable certain patients a chance to live longer lives.

For more information, visit Opdivo.com or talk to you doctor about treatment options.

INDICATION Opdivo (nivolumab) is a prescription medicine used in combination with Yervoy (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.

It is not known if OPDIVO is safe and effective in children younger than 18 years of age.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

IMPORTANTSAFETYINFORMATION forOPDIVO(nivolumab) + YERVOY(ipilimumab)

OPDIVO is a medicine that may treat certain cancers by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. Some of these problems may happen more often when OPDIVO is used in combination with YERVOY.

YERVOY can cause serious side effects in many parts of your body which can lead to death. These problems may happen anytime during treatment with YERVOY or after you have completed treatment.

Serious side effects may include:

Additional serious side effects observed during a separate study of YERVOY alone include:

Get medical help immediatelyif you develop any of these symptoms or they get worse. It may keep these problems from becoming more serious. Your healthcare team will check you for side effects during treatment and may treat you with corticosteroid or hormone replacement medicines. If you have a serious side effect, your healthcare team may also need to delay or completely stop your treatment.

OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:

Pregnancy and Nursing:

Tell your healthcare provider about:

The most common side effects of OPDIVO, when used in combination with YERVOY, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection;headache; low thyroid hormone levels (hypothyroidism); decreased weight; and dizziness.

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatch or call 1-800-FDA-1088.

Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO and YERVOY.

Michael French mfrench@familyfeatures.com 1-888-824-3337 editors.familyfeatures.com

About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c174110-3d0e-4a76-a2bc-46e0ebc4e6a5

See the original post:
Advances in Treating Non-Small Cell Lung Cancer - GlobeNewswire

Stem Cell Antibody Market Booming Demand Leading To Exponential CAGR Growth By 2026 | Industry Growth Insights – My Kids Health

By Stell Cell Research

IndustryGrowthInsights (IGI), one of the worlds prominent market research firms has announced a novel report on Global Stem Cell Antibody Market. The report contains vital insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Stem Cell Antibody market to figure out and study the market needs, market size, and competition. The report incorporates data regarding the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players during the forecast period of 2020-2026.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=214552

Impact of COVID-19 on Stem Cell Antibody Market

The report also includes the impact of ongoing global crisis i.e. COVID-19 on the Stem Cell Antibody market and what the future holds for it. It provides an analysis of the effects of the pandemic on the global economy. The outbreak has directly disturbed the demand and supply chain. The report also analyzes the financial impact on firms and financial markets. IndustryGrowthInsights (IGI) has gathered insights from several delegates of the industry and got involved in the primary and secondary research to provide the clients with data and strategies to combat the market challenges during and after COVID-19 pandemic.

Benefits of buying the report:

Industry experts and research analysts have worked extensively to prepare the research report which will help you to give that extra edge in the competitive market. The market research report can be customized according to you to your needs. This means that IndustryGrowthInsights (IGI) can cover a particular product, application, or can provide a detailed analysis in the report. You can also purchase a separate report for a specific region.

You can buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=214552

Some of the major companies that are covered in this report:

PLAYERS

*Note: Additional companies can be included on request

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Application:

APPS

By Type:

TYPES

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia Pacific Europe: Germany, the UK, France, and Rest of Europe North America: The US, Mexico, and Canada Latin America: Brazil and Rest of Latin America Middle East & Africa: GCC Countries and Rest of Middle East & Africa

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is included in the report is the regional analysis to assess the global presence of the Stem Cell Antibody market. You can also opt for a yearly subscription of all the updates on the Stem Cell Antibody market.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=214552

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Stem Cell Antibody Market Overview

Global Stem Cell Antibody Market Analysis and Forecast by Type

Global Stem Cell Antibody Market Analysis and Forecast by Application

Global Stem Cell Antibody Market Analysis and Forecast by Sales Channel

Global Stem Cell Antibody Market Analysis and Forecast by Region

North America Stem Cell Antibody Market Analysis and Forecast

Latin America Stem Cell Antibody Market Analysis and Forecast

Europe Stem Cell Antibody Market Analysis and Forecast

Asia Pacific Stem Cell Antibody Market Analysis and Forecast

Asia Pacific Stem Cell Antibody Market Size and Volume Forecast by Application

Middle East & Africa Stem Cell Antibody Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, feel free to reach us! @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=214552

About IndustryGrowthInsights (IGI):

IndustryGrowthInsights (IGI) has a vast experience in making customized market research reports in various industry verticals. Our motto is to provide complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://industrygrowthinsights.com

Link:
Stem Cell Antibody Market Booming Demand Leading To Exponential CAGR Growth By 2026 | Industry Growth Insights - My Kids Health

Another Voice: Terminally ill New Yorkers need a peaceful dying option – Buffalo News

By Stem Cell Medicine

The other one of us, Deborah Stern, suffers from myelodysplastic syndrome/chronic myelomonocytic leukemia. I want very much to live as long as I can and to be there for my family and friends. I am on weekly chemo to try to give myself more time. Ultimately, the only possibility of a cure for me would be a stem cell transplant and so far there have been no donor matches for me located in the world registries.

I dont believe God wants people to suffer. Knowing I have a peaceful dying option would enable me to live the rest of my life with a much better quality of life, taking the worry of increased suffering off the table.

It gave us great comfort that Gov. Andrew M. Cuomo recognized our reality when he announced his support for the Medical Aid in Dying Act last year: Pass the bill the older we get and the better medicine gets, the more weve seen people suffer for too, too long, he said. But we need our Assembly and Senate representatives to act before its too late for us.

Most New Yorkers, including doctors, agree. They also support medical aid in dying, according to recent polling by Quinnipiac University and Medscape-WebMD, respectively.

Washington, D.C., and nine states allow terminally ill adults to have the option of medical aid in dying, including New Yorks neighbors in Maine, New Jersey and Vermont.

Here is the original post:
Another Voice: Terminally ill New Yorkers need a peaceful dying option - Buffalo News

Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with…

By Stem Cell Medicine

Details Category: Small Molecules Published on Tuesday, 28 July 2020 17:27 Hits: 114

SAN FRANCISCO, CA, USA I July 28, 2020 I Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in oncology, announced today that the first patient has been dosed with CB-5339 in a Phase 1 clinical trial of patients with relapsed/refractory acute myeloid leukemia (AML) or relapsed/refractory intermediate or high-risk myelodysplastic syndrome (MDS). CB-5339 is a potent and selective, second-generation, oral small molecule inhibitor of VCP/p97.

We are pleased to begin patient enrollment of our clinical study in AML and MDS, which marks an important milestone in evaluating the initial safety and potential therapeutic benefit of VCP inhibitors for patients with cancer, said Amy Burroughs, president and chief executive officer of Cleave. This clinical program stems from more than a decade of research by scientists who have identified VCP/p97 as a pan-cancer core fitness target that is essential for cancer cell growth and survival.

The primary objectives of the Phase 1 study are to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of CB-5339. Additional objectives are to examine the pharmacokinetic parameters and estimate the anti-tumor effects of CB-5339. CB-5339 is administered orally for four days, followed by a three-day treatment-free period weekly in successive 28-day cycles. The trial is expected to enroll 50 to 60 patients in the United States and Australia and does not select or exclude patients based on tumor genetic profile.

Despite several new drug approvals in the last several years, there remains an urgent need for well-tolerated, effective therapies for patients with myeloid malignancies, said Courtney DiNardo, MD, MSCE, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. We are eager to study CB-5339 as a unique oral therapy that could benefit our AML and MDS patients perhaps even regardless of their mutational status - by disrupting stress pathways that are critical to cancer cells.

In addition to the AML/MDS trial, the National Cancer Institute (NCI), part of the National Institutes of Health, is sponsoring a Phase 1 clinical trial with CB-5339 in solid tumors and lymphomas. For more information on both of these trials, please visit the AML/MDS study or the Solid Tumors/Lymphomas study at http://www.clinicaltrials.gov.

About Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Acute myeloid leukemia is a type of cancer of the blood and bone marrow, caused by mutations in the genetic material (DNA) of myeloid stem cells which result in the formation of leukemic cells. These cells, also referred to as AML cells, cannot mature into fully functional blood cells, and they multiply uncontrollably. Nearly 20,000 newly diagnosed acute myeloid leukemia patients and 12,000 deaths are expected from AML in the U.S. this year. Myelodysplastic syndromes are a group of diverse bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. Nearly 15,000 newly diagnosed cases of MDS are expected per year.

About Cleave Therapeutics

Cleave Therapeutics is a clinical-stage biopharmaceutical company focused on VCP/p97 as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer. The privately held company, based in San Francisco, is studying CB-5339, its second-generation, small molecule VCP/p97 inhibitor, in a Phase 1 clinical trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while the National Cancer Institute (NCI) is sponsoring and evaluating CB-5339 in a Phase 1 clinical trial of patients with solid tumors and lymphomas. Cleave investors include 5AM Ventures, Bristol-Myers Squibb, Orbimed, U.S. Venture Partners (USVP), Arcus Ventures, Astellas Venture Management, and Osage University Partners. For additional information, visit http://www.cleavetherapeutics.com.

SOURCE: Cleave Therapeutics

Read more here:
Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339, A Valosin-Containing Protein (VCP)/p97 Inhibitor, in Patients with...

→←